- NervGen Pharma press release (OTCQX:NGENF): Q3 GAAP EPS of -$0.07.
- NervGen had cash and investments of $14.8 million as of September 30, compared to $22.5 million as of December 31, 2022.
- The net cash burn for Q3 2023 from operating and investing activities was approximately $1.6 million.
- Research and development expenses net of grant funding received were $0.8 million for the three months ended September 30.